Lina M. Olsson

Lund, M, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Integrated spatially guided transcriptomics and multiplex imaging identify a high-risk CD163+/CD11c-subgroup in diffuse large B-cell lymphoma.

Integrated spatially guided transcriptomics and multiplex imaging identify a high-risk CD163+/CD11c-subgroup in diffuse large B-cell lymphoma.

Journal: Haematologica

Published: December 23, 2025

Distinct immune microenvironments in ovarian cancer subtypes indicate potential for immunotherapies.

Distinct immune microenvironments in ovarian cancer subtypes indicate potential for immunotherapies.

Journal: Journal of translational medicine

Published: November 09, 2025

Prognostic Role of EMR1 in Lymph Nodes and Primary Tumors of Colon Cancer Patients.

Prognostic Role of EMR1 in Lymph Nodes and Primary Tumors of Colon Cancer Patients.

Journal: Advanced biology

Published: October 21, 2025

Combined serine protease PRSS22 and CEA mRNA analysis identifies the majority of colon cancer patients that recur within 12 years.

Combined serine protease PRSS22 and CEA mRNA analysis identifies the majority of colon cancer patients that recur within 12 years.

Journal: Frontiers in oncology

Published: May 27, 2025

Altered immune signatures in breast cancer lymph nodes with metastases revealed by spatial proteome analyses.

Altered immune signatures in breast cancer lymph nodes with metastases revealed by spatial proteome analyses.

Journal: Journal of translational medicine

Published: November 15, 2024

Quantification and Profiling of Early and Late Differentiation Stage T Cells in Mantle Cell Lymphoma Reveals Immunotherapeutic Targets in Subsets of Patients.

Quantification and Profiling of Early and Late Differentiation Stage T Cells in Mantle Cell Lymphoma Reveals Immunotherapeutic Targets in Subsets of Patients.

Journal: Cancers

Published: May 02, 2024

LGR6 is a prognostic biomarker for less differentiated tumors in lymph nodes of colon cancer patients.

LGR6 is a prognostic biomarker for less differentiated tumors in lymph nodes of colon cancer patients.

Journal: Frontiers in oncology

Published: February 28, 2024

CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression.

CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression.

Journal: Blood advances

Published: October 26, 2023

Detection of lymph node metastasis in colon cancer by ectopically expressed fibroblast markers FOXQ1 and THBS2.

Detection of lymph node metastasis in colon cancer by ectopically expressed fibroblast markers FOXQ1 and THBS2.

Journal: Frontiers in oncology

Published: September 19, 2023

qRT-PCR analysis of CEACAM5, KLK6, SLC35D3, MUC2 and POSTN in colon cancer lymph nodes-An improved method for assessment of tumor stage and prognosis.

qRT-PCR analysis of CEACAM5, KLK6, SLC35D3, MUC2 and POSTN in colon cancer lymph nodes-An improved method for assessment of tumor stage and prognosis.

Journal: International journal of cancer

Published: May 31, 2023

Clinical Significance of Stem Cell Biomarkers EpCAM, LGR5 and LGR4 mRNA Levels in Lymph Nodes of Colon Cancer Patients.

Clinical Significance of Stem Cell Biomarkers EpCAM, LGR5 and LGR4 mRNA Levels in Lymph Nodes of Colon Cancer Patients.

Journal: International journal of molecular sciences

Published: December 13, 2021

The myeloid cell biomarker EMR1 is ectopically expressed in colon cancer.

The myeloid cell biomarker EMR1 is ectopically expressed in colon cancer.

Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Published: September 06, 2021

Showing 1-12 of 24

Last Updated: 09/26/2026